The University of Virginia (UVA) Cancer Center is directed by Michael J. Weber, PhD. He is assisted in this role by the Senior Leadership team comprised of: Paula M. Fracasso, MD, PhD (Deputy Director and Associate Director for Clinical Research), Jay W. Fox, PhD (Associate Director for Laboratory Research Infrastructure), Dina G. Halme, PhD (Associate Director for Research Administration), Christopher A. Moskaluk, MD, PhD (Associate Director for Translational Infrastructure), and Sarah J. Parsons, PhD (Associate Director for Laboratory Research). Members of the Senior Leadership each possess a different area of responsibility, perspective, and expertise. Together they form a strong center to the matrix that is the UVA Cancer Center. Dr. Weber and the Senior Leadership use consensus building in interacting with UVA departments and committees and with the Program Leaders to formulate priorities, develop strategic plans, and allocate resources. They provide recommendations on integrating research between the Programs, discuss collaborations and discoveries within the Programs, assist in oversight of the Shared Resources, and help identify synergies in basic and clinical research and in infrastructure. Collectively, they ensure that the allocation of resources is aligned with the strategic vision of the Cancer Center. A subset of the Senior Leadership team (Weber, Fracasso, Halme, and Parsons) meets weekly and the entire team meets monthly at the CCSG Executive Committee meeting. They provide direct counsel and recommendations to the Director based on these interactions. Final authority for decisions on behalf of the UVA Cancer Center resides with the Director.

Public Health Relevance

; Funds to provide partial support for Senior Leadership enables the UVA Cancer Center to develop and implement its strategic priorities. The percent effort requested from the CCSG is a small portion of the total effort each of the leaders actually expends on Cancer Center priorities.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA044579-21
Application #
8231151
Study Section
Subcommittee G - Education (NCI)
Project Start
2012-06-05
Project End
2017-01-31
Budget Start
2012-06-05
Budget End
2013-01-31
Support Year
21
Fiscal Year
2012
Total Cost
$384,077
Indirect Cost
$140,476
Name
University of Virginia
Department
Type
DUNS #
065391526
City
Charlottesville
State
VA
Country
United States
Zip Code
22904
Borten, Michael A; Bajikar, Sameer S; Sasaki, Nobuo et al. (2018) Automated brightfield morphometry of 3D organoid populations by OrganoSeg. Sci Rep 8:5319
Olson, Kristine C; Kulling Larkin, Paige M; Signorelli, Rossana et al. (2018) Vitamin D pathway activation selectively deactivates signal transducer and activator of transcription (STAT) proteins and inflammatory cytokine production in natural killer leukemic large granular lymphocytes. Cytokine 111:551-562
Pfister, Katherine; Pipka, Justyna L; Chiang, Colby et al. (2018) Identification of Drivers of Aneuploidy in Breast Tumors. Cell Rep 23:2758-2769
Carhart, Miev Y; Schminkey, Donna L; Mitchell, Emma M et al. (2018) Barriers and Facilitators to Improving Virginia's HPV Vaccination Rate: A Stakeholder Analysis With Implications for Pediatric Nurses. J Pediatr Nurs 42:1-8
Hao, Yi; Bjerke, Glen A; Pietrzak, Karolina et al. (2018) TGF? signaling limits lineage plasticity in prostate cancer. PLoS Genet 14:e1007409
Obeid, Joseph M; Kunk, Paul R; Zaydfudim, Victor M et al. (2018) Immunotherapy for hepatocellular carcinoma patients: is it ready for prime time? Cancer Immunol Immunother 67:161-174
Wallrabe, Horst; Svindrych, Zdenek; Alam, Shagufta R et al. (2018) Segmented cell analyses to measure redox states of autofluorescent NAD(P)H, FAD & Trp in cancer cells by FLIM. Sci Rep 8:79
Olmez, Inan; Love, Shawn; Xiao, Aizhen et al. (2018) Targeting the mesenchymal subtype in glioblastoma and other cancers via inhibition of diacylglycerol kinase alpha. Neuro Oncol 20:192-202
Wang, T Tiffany; Yang, Jun; Zhang, Yong et al. (2018) IL-2 and IL-15 blockade by BNZ-1, an inhibitor of selective ?-chain cytokines, decreases leukemic T-cell viability. Leukemia :
Yao, Nengliang; Zhu, Xi; Dow, Alan et al. (2018) An exploratory study of networks constructed using access data from an electronic health record. J Interprof Care :1-8

Showing the most recent 10 out of 539 publications